Meta-analysis of the impact of de novo and acquired <i>EGFR</i> T790M mutations on the prognosis of patients with non-small cell lung cancer receiving EGFR-TKIs.

Onco Targets Ther · 2017 · PMC5411171 · PMID 28479857

Europe PMC DOI

hedged sentences

0.0510

closest p · 1.0× alpha

0.0510

boldest claim

The sentences

a trend toward significanceP =0.051so close (0.05 < p ≤ 0.1)

A trend toward significance of worsening ORR (RR 0.86, P =0.051) was evident.

also in 3,729 other papers

a decreasing trendno p-value reported

an increasing trendno p-value reported

25 , 27 , 47 One study involving 83 patients with activating EGFR mutations showed that patients with an increasing trend for T790M quantity from pretreatment to posttreatment of EGFR-TKIs had superior PFS and OS, compared to patients with a decreasing trend of T790M quantity. 44 , 48 Thanks to recent advances in the era of third-generation EGFR-TKIs such as osimertinib, it is better understood that patients with acquired T790M mutation will benefit more from osimertinib treatment than patients without T790M mutation.

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.